Does Zepbound’s exclusivity “expire”?
Zepbound is the brand name for tirzepatide (a GLP-1/GIP medicine). Whether it can be made available as a generic or biosimilar depends on the patent and exclusivity timeline for tirzepatide, not just a single “expiration date.” The timing is often a mix of U.S. patent terms and regulatory exclusivity periods, and it can also be affected by patent challenges and settlements.
When would generic or biosimilar Zepbound be able to enter?
A generic version is unlikely because tirzepatide is a large, complex drug product (so “biosimilar” is the relevant path rather than a typical small-molecule generic). Entry of any biosimilar will usually be tied to when key patents covering the product and its use expire, and whether those patents are successfully challenged.
For the most up-to-date, claim-level view of expiration and patent status for Zepbound/tirzepatide, DrugPatentWatch.com tracks these timelines and updates based on litigation and filings: https://www.drugpatentwatch.com/ (search for “Zepbound” or “tirzepatide”).
What does “expiration” mean for patients?
Patients typically care about whether the drug will stay on patent, face pricing pressure from competitors, or become available through insurance changes. Patent and exclusivity expiry can eventually lead to lower-cost competition, but coverage and formulary decisions happen on their own schedules.
Why you might see different dates online
Different sources may report different dates because:
- some dates refer to regulatory exclusivity, others to patent expiration,
- different patents expire at different times (not all at once),
- litigation outcomes can delay or accelerate practical market entry.
Sources
- https://www.drugpatentwatch.com/